Antimicrobial Peptides and Cationic Nanoparticles: A Broad-Spectrum Weapon to Fight Multi-Drug Resistance Not Only in Bacteria

Int J Mol Sci. 2022 May 29;23(11):6108. doi: 10.3390/ijms23116108.

Abstract

In the last few years, antibiotic resistance and, analogously, anticancer drug resistance have increased considerably, becoming one of the main public health problems. For this reason, it is crucial to find therapeutic strategies able to counteract the onset of multi-drug resistance (MDR). In this review, a critical overview of the innovative tools available today to fight MDR is reported. In this direction, the use of membrane-disruptive peptides/peptidomimetics (MDPs), such as antimicrobial peptides (AMPs), has received particular attention, due to their high selectivity and to their limited side effects. Moreover, similarities between bacteria and cancer cells are herein reported and the hypothesis of the possible use of AMPs also in anticancer therapies is discussed. However, it is important to take into account the limitations that could negatively impact clinical application and, in particular, the need for an efficient delivery system. In this regard, the use of nanoparticles (NPs) is proposed as a potential strategy to improve therapy; moreover, among polymeric NPs, cationic ones are emerging as promising tools able to fight the onset of MDR both in bacteria and in cancer cells.

Keywords: antibiotics; anticancer drugs; antimicrobial peptides; cationic nanoparticles; multi-drug resistance.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Antimicrobial Cationic Peptides* / pharmacology
  • Antimicrobial Cationic Peptides* / therapeutic use
  • Antimicrobial Peptides
  • Bacteria
  • Drug Resistance, Multiple
  • Nanoparticles*

Substances

  • Anti-Bacterial Agents
  • Antimicrobial Cationic Peptides
  • Antimicrobial Peptides

Grants and funding

This research received no external funding.